Arkansas Passes First-of-its-Kind Bill to Counter Pharma’s 340B Contract Pharmacy Moves

Arkansas state lawmakers this week passed what is thought to be the first bill in the nation to address drug manufacturers' denials of 340B pricing on drugs dispensed by contract pharmacies. | Jim Bowen/Flickr

The Arkansas legislature on Tuesday passed what is believed to be the first bill nationally to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by contract pharmacies.

The state Senate passed the bipartisan bill,

Read More »

Vermont AG Issues Subpoena to Novartis for 340B Documents and Information

Novartis is the second known drug manufacturer subpoenaed by the Vermont attorney general over manufacturer denials of or restrictions on 340B pricing for drugs shipped to contract pharmacies.

Vermont’s top law enforcement official has asked a second drug manufacturer—Novartis—for documents and information concerning the company’s participation in the 340B program in the state.

Tuesday in its interim financial report for the first quarter of 2021, the Swiss

Read More »

Tech Firm Convening Working Group to Address 340B Duplicate Discounts

Susanne Somerville, CEO of life sciences information sharing consulting firm Chronicled, thinks blockchain technology could be the solution to 340B duplicate discounts.

A Bay Area health care tech firm is convening a work group to try to solve the problem of duplicate 340B discounts and Medicaid rebates on the same drugs.

San Francisco-based Chronicled said in a statement issued on Tuesday

Read More »

Biden Wants to Let Medicare Negotiate Drug Prices, but Not Via His American Families Plan

President Biden applauds Vice President Kamala Harris and House Speaker Nancy Pelosi prior to his speech before a joint session of Congress last night. The event marked the first time in history that two women were seated in the two positions of authority and honor directly behind the president during such a speech. | @POTUS Twitter

President Biden has left out of his American Families human-capital investment plan drug pricing reforms that Democratic leaders in Congress have pressed him hard to add. House Speaker Nancy Pelosi (D-Calif.), House Energy and Commerce (E&C) Chair Frank Pallone (D-N.J.),

Read More »

Key Factors To Consider To Ensure Effective Management of a 340B Pharmacy Program

SPONSORED CONTENT by Ross Halsne

It’s becoming increasingly difficult for Covered Entities (CEs) to effectively manage their 340B pharmacy programs.  Often times understaffed relative to the task of handling the myriad of challenges that come with managing a 340B program, they face a seemingly constant barrage of maneuvering and attacks aimed at reducing their 340B benefit.  In response, many Covered Entities are evaluating new strategies to strengthen or reinvigorate

Read More »

Hospitals Could Get Another Shot to Intervene in AstraZeneca’s 340B Lawsuit

A federal judge in Delaware yesterday left the door open to letting hospital groups participate as third parties in a drugmaker’s lawsuit challenging the federal government’s 340B program contract pharmacy enforcement mechanisms. | Shutterstock

A federal judge in Delaware yesterday declined to add hospital groups as third parties to a drugmaker’s lawsuit challenging the federal government’s 340B program contract pharmacy enforcement mechanisms. But he left the door open to letting the groups participate as

Read More »

Nonprofit Generic Drugmaker Civica Is Providing Refunds for 340B Overcharges

Nonprofit generic drug manufacturer Civica said it has updated its 340B pricing as it obtains baseline average manufacturer price (AMP) data from generic drug manufacturers that make the same products. | Marco Verch https://www.flickr.com/photos/30478819@N08/

Civica, the nonprofit generic drug manufacturer that health systems created in response to drug shortages, owes 340B covered entities refunds for overcharges on 13 NDCs from April 13, 2020 through Feb. 23, 2021.

Civica posted a public notice this

Read More »

Will Biden’s American Families Plan Include an Rx Drug Pricing Measure?

There is a rift between President Biden and House Democrats over whether to include provisions to lower drug prices in his American Families plan, or deal with drug pricing later in another bill. | Official White House Photo by Adam Schultz

President Biden might exclude legislation to reduce what consumers and the federal government pay for prescription drugs from his American Families human and capital investment initiative, news organizations report this morning. Biden is scheduled to describe his infrastructure investment plan

Read More »

Breaking News

BREAKING: Judge Nixes Hospital Groups’ Participation in AstraZeneca’s 340B Contract Pharmacy Case

Six hospital groups cannot participate as third parties in drug manufacturer AstraZeneca’s lawsuit against the government over its 340B contract pharmacy requirements, a judge ruled this morning in federal district court in Wilmington, Del. (pictured).

A federal district judge in Wilmington, Del., ruled this morning that six hospital groups cannot participate as third parties in drug manufacturer AstraZeneca’s lawsuit against the government over its 340B contract pharmacy requirements.

In a ruling delivered from the bench,

Read More »

340B Providers Escape Bullet in House Dem Rx Bill, but Not in GOP Version

U.S. House E&C Chair Frank Pallone this morning re-introduced a major drug pricing bill from the last session of Congress, minus language from last year's version strongly opposed by 340b covered entities. | C-SPAN

UPDATE Thursday, April 22, 2021, 1:00 p.m. EDT—U.S. House Energy and Commerce (E&C) Chair Frank Pallone this morning introduced a significantly slimmed-down version of H.R. 3, the drug pricing bill that the House passed during the last session of Congress

Read More »